Larimar Therapeutics (LRMR) Income towards Parent Company (2013 - 2025)

Larimar Therapeutics' Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$65.5 million for Q4 2025.

• Quarterly Income towards Parent Company rose 67.93% year-over-year to -$65.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.4 million (up 37.55% YoY) and the FY2025 annual result came in at -$174.0 million, up 34.07% from the prior year.
• Income towards Parent Company was -$65.5 million for Q4 2025 at Larimar Therapeutics, down from -$50.7 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$9.7 million in Q1 2023 and bottomed at -$204.3 million in Q4 2024.
• A 5-year average of -$52.6 million and a median of -$26.7 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company sank 186.01% — and 2025, when it soared 67.93%.
• Larimar Therapeutics' Income towards Parent Company stood at -$133.1 million in 2021, then decreased by 6.14% to -$141.3 million in 2022, then retreated by 10.38% to -$155.9 million in 2023, then sank by 31.03% to -$204.3 million in 2024, then surged by 67.93% to -$65.5 million in 2025.
• Business Quant data shows LRMR's Income towards Parent Company at -$65.5 million in Q4 2025, -$50.7 million in Q3 2025, and -$29.0 million in Q2 2025.